Nuvilex  (OTCQB: NVLX) has more than $25-million put into its “Cell-in-a-Box™” technology, and as the company gets closer to the beginning of its 3rd|third stage pancreas can cer testing, it may be growing into a “gem” at just the right time!

If Big Pharma is on the searching for deals that can resupply their own pipelines as long-time patents continue to expire, they’re surely looking at entities bigger than Nuvilex. But, in turn, mid-level companies are padding their own pipelines this enhanced pipeline to the “big boys.”

If the science proves out, Big Pharma can jump in and acquire smaller companies, like Nuvilex, Inc., evading a lot of the risks and the great outflow of time linked to the early phases of development of disease treatments.

The use of research materials distributed by the author is done at your own risk.  You are encouraged to do your own research before making any investment decision with respect to the secu rity discussed herein. The author has not been rewarded by any entity in connection with the disbursement of these materials. You should presume that as of the date of this report or letter, the author, possibly along with or through our owners, affiliates, employees and/or consultants, (communally referred to as the author) has a position in all company shares (and/or options of the shares) covered herein that is consistent with the position set forth in our report. In connection with NVLX, the author has taken a long position. Following the distribution of any report or letter, the author plans to continue engaging in trnsactns in the security covered herein, and we may be long, short, and/or neutral at any time hereafter regardless of our initial position and we preserve the right to procure or trade all or part of our position at any time without notice.  This practice could end in our trading securities at any time before, during, and/or after the disbursement of this report. Read full disclaimer


10200 Forrest Gren Blvd., Ste. 112, Louisville, KY 40223